Currently, targetable genetic alterations for NSCLC include epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS-1), Kirsten rat sarcoma virus (KRAS), B-Raf proto-oncogene (BRAF), MET proto-oncogene (MET), human epidermal growth factor receptor (HER2), neurotrophic tyrosine receptor kinase (NTRK), and the rearranged during transfection (RET) gene [7]. The gene discussed is MET; the disease is non-small cell lung carcinoma.